Efficacy and Safety of Intravenous Iron Therapy for Functional Iron Deficiency Anemia in Hemodialysis Patients: A Meta-Analysis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American Journal of Nephrology

• Publication date

  2014-02-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000358336PMID 24513913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

  2013cited by this paper
• Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.

  2013cited by this paper
• The initial impact of Medicare's new prospective payment system for kidney dialysis.

  2013cited by this paper
• Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.

  2013cited by this paper
• Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).

  2013cited by this paper
• Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

  2012cited by this paper
• Notice

  2012cited by this paper
• KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease.

  2011cited by this paper
• The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.

  2011cited by this paper
• Acute Oxidative Stress following Intravenous Iron Injection in Patients on Chronic Hemodialysis: A Comparison of Iron-Sucrose and Iron-Dextran

  2010cited by this paper
• Transferrin receptor expression on reticulocytes as a marker of iron status in dialyzed patients

  2010cited by this paper
• Influence of Intravenous Iron Therapy on Novel Markers of Iron Deficiency

  2010cited by this paper
• Diagnosis of iron deficiency in patients undergoing hemodialysis.

  2010cited by this paper
• Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population

  2010cited by this paper
• A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

  2010cited by this paper
• Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

  2009cited by this paper
• Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

  2009cited by this paper
• Low-Molecular-Weight Iron Dextran in the Management of Renal Anaemia in Patients on Haemodialysis – the IDIRA Study

  2009cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• Empirical Methods to Calculate an Erythropoiesis-Stimulating Agent Dose Conversion Ratio in Nondialyzed Patients with Chronic Kidney Disease

  2009cited by this paper
• Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.

  2008cited by this paper
• Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.

  2008cited by this paper
• Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.

  2008cited by this paper
• Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.

  2008cited by this paper
• Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

  2008cited by this paper
• Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.

  2008cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

  2007cited by this paper
• Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

  2007cited by this paper
• Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.

  2007cited by this paper
• The Effect of Intravenous Iron on Oxidative Stress in Hemodialysis Patients at Various Levels of Vitamin C

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

  2006cited by this paper
• Sodium ferric gluconate complex maintenance therapy in children on hemodialysis

  2006cited by this paper
• Faculty Opinions recommendation of Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.

  2006cited by this paper
• Assessing iron status: beyond serum ferritin and transferrin saturation.

  2006cited by this paper
• Influence of Parenteral Iron Therapy and Oral Vitamin E Supplementation on Neutrophil Respiratory Burst in Chronic Hemodialysis Patients

  2005cited by this paper
• Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.

  2005cited by this paper
• Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

  2004cited by this paper
• [Iron replacement in hemodialysis patients with a normal serum ferritin level].

  2004cited by this paper
• Managing mineral balance in end-stage renal disease.

  2004cited by this paper
• Iron storage indices and risk of bacterial infections in hemodialysis patients

  2004cited by this paper
• Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy.

  2004cited by this paper
• Eisensubstitution bei Hämodialysepatienten mit normalem Serumferritinspiegel1

  2004cited by this paper
• Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis

  2004cited by this paper
• Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.

  2003cited by this paper
• The Effects of Intravenous Iron Treatment on Oxidant Stress and Erythrocyte Deformability in Hemodialysis Patients

  2003cited by this paper
• Carbonyl stress induced by intravenous iron during haemodialysis.

  2003cited by this paper
• Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.

  2003cited by this paper
• Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.

  2002cited by this paper
• Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients.

  2002cited by this paper
• Continuous Intravenous Sodium Ferric Gluconate Improves Efficacy in the Maintenance Phase of EPOrHu Administration in Hemodialysis Patients

  2002cited by this paper
• Nontransferrin‐bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion

  2002cited by this paper
• A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.

  2001cited by this paper
• A randomized trial of iron deficiency testing strategies in hemodialysis patients.

  2001cited by this paper
• THE EFFECT OF AN IRON SUPPLEMENT ON SERUM ALUMINUM LEVEL AND DESFERRIOXAMINE MOBILIZATION TEST IN HEMODIALYSIS PATIENTS

  2001cited by this paper
• Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.

  2000cited by this paper
• A trial of two iron-dextran infusion regimens in chronic hemodialysis patients.

  2000cited by this paper
• Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit.

  1999cited by this paper
• Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).

  1998cited by this paper
• Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.

  1998cited by this paper
• Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Iron and infection.

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Safety of intravenous injection of iron saccharate in haemodialysis patients.

  1996cited by this paper
• Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.

  1995cited by this paper
• Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments.

  1991cited by this paper
• Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study.

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Iron and infection

  1978cited by this paper
• Renal handling of calcium and phosphate during mineralocorticoid "escape" in man.

  1972cited by this paper

• Lymph food to improve canine atopic dermatitis: a randomized, double-blinded, controlled trial in dogs with standard-care treatment

  2025cites this paper
• Hepcidin as a marker of iron status in patients with chronic kidney disease.

  2025cites this paper
• Study of Correlation of Iron Profile of Elderly Patients with Heart Failure in a Tertiary Care Center.

  2025cites this paper
• Efficacy and safety of high-dose intravenous iron in the treatment of iron-deficiency anemia in patients undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Erythropoietin impact on serum ferritin levels in dialysis-dependent chronic kidney disease patients receiving iron therapy.

  2025cites this paper
• Safety of High-Dose Intravenous Iron in Hemodialysis Patients: Results from the National Health Insurance Service (2019–2020) in South Korea

  2024cites this paper
• Iron deficiency in dogs suffering from atopic dermatitis

  2024cites this paper
• Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction

  2024cites this paper
• Association of Estimated Total Body Iron with All-Cause Mortality in Japanese Hemodialysis Patients: The Miyazaki Dialysis Cohort Study

  2023cites this paper
• Real-world experience of intravenous iron sucrose supplementation and dynamics of soluble transferrin receptor and hepcidin in a Spanish cohort of absolute iron deficient patients.

  2023cites this paper
• Ameliorating Atopy by Compensating Micronutritional Deficiencies in Immune cells: a Double-Blind Placebo-Controlled Pilot Study.

  2022cites this paper
• Iron-Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores

  2022cites this paper
• Predictors of iron versus erythropoietin responsiveness in anemic hemodialysis patients

  2022cites this paper
• A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose

  2022cites this paper
• Efficacy and safety of intravenous iron with different frequencies for renal anaemia: A systematic review and meta‐analysis

  2022cites this paper
• Patient Blood Management Strategies to Avoid Transfusions in Body Contouring Operations: Controlled Clinical Trial

  2021cites this paper
• Evaluation of ferric carboxymaltose treatment efficacy in women with postpartum iron deficiency anemia

  2021cites this paper
• Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis.

  2021cites this paper
• Clinical significance of a novel reticulocyte‐based erythropoietin resistance index in HD patients: A retrospective study

  2021cites this paper
• The Impact of Iron Supplementation for Treating Anemia in Patients with Chronic Kidney Disease: Results from Pairwise and Network Meta-Analyses of Randomized Controlled Trials

  2020cites this paper
• Potential hazards of recent trends in liberal iron use for renal anemia

  2020cites this paper
• A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom

  2020cites this paper
• Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial

  2020cites this paper
• Low transferrin saturation (TSAT) and high ferritin levels are significant predictors for cerebrovascular and cardiovascular disease and death in maintenance hemodialysis patients

  2020cites this paper
• The Influence of Inflammation on Anemia in CKD Patients

  2020cites this paper
• Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia

  2020cites this paper
• Intravenous iron supplementation does not increase infectious disease risk in hemodialysis patients: a nationwide cohort-based case-crossover study

  2019cites this paper
• Assessment of Iron Profile among Sudanese Patients with Chronic Renal Failure in Shendi Town

  2019cites this paper
• Anemia in Chronic Kidney Disease

  2019cites this paper
• Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

  2019cites this paper
• Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

  2019cites this paper
• Iron Deficiency in Heart Failure

  2019cites this paper
• Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.

  2019cites this paper
• Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis

  2019cites this paper
• Anemia of Inflammation with An Emphasis on Chronic Kidney Disease

  2019cites this paper
• Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis.

  2018cites this paper
• Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease

  2018cites this paper
• Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.

  2017cites this paper
• Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13. Nephrology Dialysis Transplantation , 32 (4), 692-698.

  2017cites this paper
• Safety of intravenous iron in hemodialysis patients

  2017cites this paper
• Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients

  2017cites this paper
• Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis

  2017cites this paper
• Anemia in Patients with Chronic Kidney Disease: Current Screening and management Approaches

  2016cites this paper
• Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers

  2016cites this paper
• Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.

  2016cites this paper
• Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.

  2016cites this paper
• Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13

  2016cites this paper
• Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners

  2016cites this paper
• Mineral-related hormones are closely associated with the titers of antibody against hepatitis B surface antigen in prevalent dialysis patients

  2016cites this paper
• Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in hemodialysis patients

  2016cites this paper
• Iron Localization and Infectious Disease in Chronic Kidney Disease Patients

  2016cites this paper
• Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients

  2016cites this paper
• Anesthesia for Patients with Anemia.

  2016cites this paper
• Investigational therapies for renal disease-induced anemia

  2016cites this paper
• Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region

  2016cites this paper
• Safety concerns about intravenous iron therapy in patients with chronic kidney disease

  2016cites this paper
• Anemia and high therapeutic doses of recombinant human erythropoietin in chronic kidney disease - a linkage of risk?

  2016cites this paper
• Optimal management of perioperative anemia: current perspectives

  2015cites this paper
• Improving Erythropoiesis Stimulating Agents'Responsiveness in Haemodialysis with Less Iron: an Observational Study

  2015cites this paper
• Iron management in chronic kidney disease: Global Outcomes” (KDIGO) Controversies Conference

  2015cites this paper
• Iron Management in Chronic Kidney Disease : Report from a Kidney Disease : Improving Global Outcomes ( KDIGO ) Controversies Conference

  2015cites this paper
• Considerations and challenges in defining optimal iron utilization in hemodialysis.

  2015cites this paper
• Immune disorders in hemodialysis patients.

  2015cites this paper
• The safety of intravenous iron preparations: systematic review and meta-analysis.

  2015cites this paper
• Improving erythropoiesis stimulating agents' responsiveness in haemodialysis with less iron: an observational study Melhorar a resposta aos estimuladores da eritropoiese em hemodiálise com menos ferro: estudo observacional

  2015cites this paper
• Blood conservation strategies and the management of perioperative anaemia

  2015cites this paper
• Aproximación al diagnóstico y tratamiento de la anemia crónica secundaria a causas digestivas

  2014cites this paper
• [Approach to the diagnosis and treatment of chronic anemia secondary to gastrointestinal diseases].

  2014cites this paper
• Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies

  2014cites this paper
• Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.

  2008cites this paper